{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:26:04Z","timestamp":1773645964668,"version":"3.50.1"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamainternmed.2021.7171","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T16:01:13Z","timestamp":1639411273000},"page":"206","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications"],"prefix":"10.1001","volume":"182","author":[{"given":"Kim A.","family":"Tran","sequence":"first","affiliation":[{"name":"College of Pharmacy, Oregon State University at Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Harrod","sequence":"additional","affiliation":[{"name":"Center for Evidence-based Policy, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis N.","family":"Bourdette","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul A.","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Department of Medicine, Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Hartung","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Oregon State University at Oregon Health & Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"irv210001r1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.ajkd.2018.12.025","article-title":"Repository corticotropin versus glucocorticoid for nephrotic syndrome: when will we see the evidence?","volume":"74","author":"Hartung","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"152","key":"irv210001r2","first-page":"14457","article-title":"Corticotropin for parenteral use: drugs for human use: drug efficacy study implementation.","volume":"36","year":"1971","journal-title":"Fed Regist"},{"issue":"11","key":"irv210001r5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/M18-3513","article-title":"Older drugs with limited trial evidence: are they worth the expense? the case of repository corticotropin marketed as H. P. Acthar Gel.","volume":"170","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"irv210001r7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jamainternmed.2017.3631","article-title":"Trends and characteristics of US Medicare spending on repository corticotropin.","volume":"177","author":"Hartung","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"irv210001r8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/L19-0519","article-title":"Older drugs with limited trial evidence: are they worth the expense?","volume":"171","author":"Hartung","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"irv210001r9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0482","article-title":"Industry payments to physician specialists who prescribe repository corticotropin.","volume":"1","author":"Hartung","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"5","key":"irv210001r11","first-page":"250","article-title":"H. P. Acthar Gel and cosyntropin review: clinical and financial implications.","volume":"34","author":"Gettig","year":"2009","journal-title":"P T"},{"issue":"8","key":"irv210001r12","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s12325-017-0569-9","article-title":"Clinical and economic evaluation of repository corticotropin injection: a narrative literature review of treatment efficacy and healthcare resource utilization for seven key indications.","volume":"34","author":"Philbin","year":"2017","journal-title":"Adv Ther"},{"issue":"7","key":"irv210001r13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7326\/M18-2205","article-title":"Scoping reviews and systematic reviews: is it an either\/or question?","volume":"169","author":"Chang","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"irv210001r14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation.","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"irv210001r17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/08830738030180030801","article-title":"Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms.","volume":"18","author":"Askalan","year":"2003","journal-title":"J Child Neurol"},{"issue":"3","key":"irv210001r18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"issue":"11","key":"irv210001r19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archneur.1986.00520110007005","article-title":"Infantile spasms. comparative trial of nitrazepam and corticotropin.","volume":"43","author":"Dreifuss","year":"1986","journal-title":"Arch Neurol"},{"issue":"5 Pt 1","key":"irv210001r20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0022-3476(05)81379-4","article-title":"High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms.","volume":"124","author":"Hrachovy","year":"1994","journal-title":"J Pediatr"},{"issue":"6","key":"irv210001r21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/epi.1980.21.issue-6","article-title":"A controlled study of ACTH therapy in infantile spasms.","volume":"21","author":"Hrachovy","year":"1980","journal-title":"Epilepsia"},{"issue":"4","key":"irv210001r22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0022-3476(83)80606-4","article-title":"Double-blind study of ACTH vs prednisone therapy in infantile spasms.","volume":"103","author":"Hrachovy","year":"1983","journal-title":"J Pediatr"},{"issue":"3","key":"irv210001r23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ana.24594","article-title":"Response to treatment in a prospective national infantile spasms cohort.","volume":"79","author":"Knupp","year":"2016","journal-title":"Ann Neurol"},{"issue":"2","key":"irv210001r24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/epi.1983.24.issue-2","article-title":"A prospective study of infantile spasms: clinical and therapeutic correlations.","volume":"24","author":"Lombroso","year":"1983","journal-title":"Epilepsia"},{"issue":"6","key":"irv210001r25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0387-7604(96)00045-9","article-title":"Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy.","volume":"18","author":"Zafeiriou","year":"1996","journal-title":"Brain Dev"},{"issue":"8","key":"irv210001r26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1212\/WNL.39.8.1027","article-title":"Treatment of infantile spasms with high-dose ACTH: efficacy and plasma levels of ACTH and cortisol.","volume":"39","author":"Snead","year":"1989","journal-title":"Neurology"},{"issue":"2","key":"irv210001r27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12098-018-2782-1","article-title":"Corticotrophin-ACTH in comparison to prednisolone in West syndrome\u2014a randomized study.","volume":"86","author":"Gowda","year":"2019","journal-title":"Indian J Pediatr"},{"issue":"2","key":"irv210001r28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp.48.2.157","article-title":"Intravenous methylprednisolone for multiple sclerosis in relapse.","volume":"48","author":"Barnes","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"irv210001r29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1756285616670060","article-title":"Adrenocorticotropic hormone versus methylprednisolone added to interferon \u00df in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.","volume":"10","author":"Berkovich","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"irv210001r30","first-page":"71","article-title":"Double-blind study of the effect of corticotropin treatment in multiple sclerosis.","volume":"55","author":"Boman","year":"1966","journal-title":"Ann Med Intern Fenn"},{"issue":"1","key":"irv210001r31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000116368","article-title":"Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. clinical, cerebrospinal fluid and neurophysiological results.","volume":"29","author":"Milanese","year":"1989","journal-title":"Eur Neurol"},{"issue":"7513","key":"irv210001r32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(67)90850-1","article-title":"Long-term treatment of multiple sclerosis with corticotrophin.","volume":"2","author":"Millar","year":"1967","journal-title":"Lancet"},{"issue":"7212","key":"irv210001r33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S0140-6736(61)91030-3","article-title":"Multiple sclerosis. treatment of acute exacerbations with corticotrophin (A.C.T.H.).","volume":"2","author":"Miller","year":"1961","journal-title":"Lancet"},{"issue":"5","key":"irv210001r34","first-page":"1","article-title":"Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo\u2014final report.","volume":"20","author":"Rose","year":"1970","journal-title":"Neurology"},{"key":"irv210001r35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/DDDT.S19331","article-title":"Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial.","volume":"5","author":"Simsarian","year":"2011","journal-title":"Drug Des Dev Ther"},{"issue":"7","key":"irv210001r36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/WNL.39.7.969","article-title":"Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS.","volume":"39","author":"Thompson","year":"1989","journal-title":"Neurology"},{"issue":"7472","key":"irv210001r37","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0140-6736(66)92025-3","article-title":"Treatment of acute retrobulbar neuritis with corticotrophin.","volume":"2","author":"Rawson","year":"1966","journal-title":"Lancet"},{"key":"irv210001r38","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/annrheumdis-2015-eular.2092","article-title":"AB0502?H. P. Acthar\u00ae Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action.","volume":"74","author":"Gillis","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7343","key":"irv210001r39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(64)91804-5","article-title":"Side-effects of long-term treatment with corticosteroids and corticotrophin.","volume":"1","author":"Treadwell","year":"1964","journal-title":"Lancet"},{"issue":"5056","key":"irv210001r40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/bmj.2.5056.1257","article-title":"The clinical course and corticosteroid excretion of patients with rheumatoid arthritis during long-term treatment with corticotropin.","volume":"2","author":"Savage","year":"1957","journal-title":"BMJ"},{"issue":"1","key":"irv210001r41","first-page":"24","article-title":"Results of long-term treatment of rheumatoid arthritis; an attempt at a comparative evaluation of cortisone and corticotrophin therapy.","volume":"3","author":"Jordal","year":"1956","journal-title":"Dan Med Bull"},{"key":"irv210001r42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0025-7125(16)34697-1","article-title":"Cortisone, ACTH and phenylbutazone in long-term therapy of rheumatoid arthritis.","volume":"12","author":"Holbrook","year":"1955","journal-title":"Med Clin North Am"},{"issue":"2","key":"irv210001r43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-020-00199-3","article-title":"Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial.","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"5","key":"irv210001r44","article-title":"A single-site, investigator initiated open-label trial of H.P. Acthar\u00ae Gel (repository corticotropin injection) an adrenocorticotropic hormone (ACTH) analogue in subjects with moderately to severely active psoriatic arthritis (PsA).","volume":"2","author":"Fiechtner","year":"2016","journal-title":"J Dermatol Res Ther"},{"issue":"1","key":"irv210001r45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/23.1.39","article-title":"In-patient regime for the treatment of ankylosing spondylitis: an appraisal of improvement in spinal mobility and the effects of corticotrophin.","volume":"23","author":"Wordsworth","year":"1984","journal-title":"Br J Rheumatol"},{"issue":"1","key":"irv210001r46","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000240","article-title":"Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.","volume":"4","author":"Furie","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"1","key":"irv210001r47","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000180","article-title":"Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.","volume":"3","author":"Furie","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"9","key":"irv210001r48","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/0961203314532562","article-title":"Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial.","volume":"23","author":"Fiechtner","year":"2014","journal-title":"Lupus"},{"issue":"5","key":"irv210001r49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.","volume":"77","author":"Aggarwal","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"irv210001r50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis.","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"issue":"8","key":"irv210001r51","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jnnp.37.8.869","article-title":"A trial of corticotrophin gelatin injection in acute optic neuritis.","volume":"37","author":"Bowden","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"irv210001r52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.","volume":"36","author":"Bomback","year":"2012","journal-title":"Am J Nephrol"},{"issue":"4","key":"irv210001r53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI102936","article-title":"The effect of corticotropin (ACTH) on glomerular permeability to albumin in children with the nephrotic syndrome.","volume":"33","author":"Lauson","year":"1954","journal-title":"J Clin Invest"},{"issue":"141","key":"irv210001r54","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/adc.28.141.372","article-title":"A.C.T.H. in nephrosis.","volume":"28","author":"Arneil","year":"1953","journal-title":"Arch Dis Child"},{"issue":"5","key":"irv210001r55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1542\/peds.10.5.543","article-title":"Adrenocorticotrophic hormone (ACTH) therapy of the nephrotic syndrome in children.","volume":"10","author":"Metcoff","year":"1952","journal-title":"Pediatrics"},{"issue":"12:2","key":"irv210001r56","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1172\/JCI102564","article-title":"Treatment of nephrosis with pituitary adrenocorticotrophin.","volume":"30","author":"Luetscher","year":"1951","journal-title":"J Clin Invest"},{"issue":"12","key":"irv210001r57","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2215\/CJN.06890618","article-title":"Adrenocorticotropic hormone for childhood nephrotic syndrome: the ATLANTIS randomized trial.","volume":"13","author":"Wang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"irv210001r58","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H. P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"irv210001r59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1212\/WNL.15.7.654","article-title":"Further notes on disability evaluation in multiple sclerosis, with scale modifications.","volume":"15","author":"Kurtzke","year":"1965","journal-title":"Neurology"},{"issue":"11","key":"irv210001r60","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"irv210001r61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.v38:1","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"irv210001r62","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"irv210001r63","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"irv210001r64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/archderm.1989.01670140087017","article-title":"Assessment of disease progress in psoriasis.","volume":"125","author":"Marks","year":"1989","journal-title":"Arch Dermatol"},{"issue":"9","key":"irv210001r65","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Novel evidence-based systemic lupus erythematosus responder index.","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"irv210001r66","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2013-000005","article-title":"Which outcome measures in SLE clinical trials best reflect medical judgment?","volume":"1","author":"Thanou","year":"2014","journal-title":"Lupus Sci Med"},{"issue":"7","key":"irv210001r67","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus.","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"irv210001r68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"irv210001r69","first-page":"986","article-title":"SAT0248 A multicenter study assessing the efficacy and safety of repository corticotropin injection in patients with rheumatoid arthritis: preliminary interim data from the open-label treatment period.","volume":"77","author":"Fleischmann","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"irv210001r71","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","article-title":"Evidence-based guideline update: medical treatment of infantile spasms. report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.","volume":"78","author":"Go","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"irv210001r72","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task force report for the ILAE Commission of Pediatrics.","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"issue":"10","key":"irv210001r73","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1212\/01.WNL.0000127773.72699.C8","article-title":"Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.","volume":"62","author":"Mackay","year":"2004","journal-title":"Neurology"},{"key":"irv210001r16","author":"Wallace","year":"2012"},{"key":"irv210001r3","unstructured":"US Food and Drug Administration. Drug approval package: H. P. Acthar Gel (repository corticotropin) injection. July 20, 2011. Accessed April 21, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022432_hp_acthar_gel_toc.cfm"},{"key":"irv210001r4","unstructured":"First Databank. Drug pricing policy. First Databank; 2021. Accessed November 9, 2021. https:\/\/www.fdbhealth.com\/drug-pricing-policy"},{"key":"irv210001r6","unstructured":"Pollack? A. Questcor finds profits, at $28,000 a vial. New York Times. December 29, 2012. Accessed May 7, 2019. https:\/\/www.nytimes.com\/2012\/12\/30\/business\/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html"},{"key":"irv210001r10","unstructured":"Committee on Oversight and Reform, US House of Representatives. Drug pricing investigation: Mallinckrodt\u2014H. P. Acthar Gel. October 2020. Accessed April 21, 2021. https:\/\/oversight.house.gov\/sites\/democrats.oversight.house.gov\/files\/Mallinckrodt%20Staff%20Report%2010-01-20%20PDF.pdf"},{"key":"irv210001r15","unstructured":"Hartung D. Acthar protocol. Center for Open Science. October 10, 2019. Updated December 12, 2019. Accessed November 9, 2021. https:\/\/osf.io\/yvebu\/?view_only=08fae5dcdc6546019c58620fda60ef1a"},{"key":"irv210001r70","unstructured":"US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. US Department of Health and Human Services; 1998. Accessed September 16, 2021. https:\/\/www.gmp-compliance.org\/files\/guidemgr\/clineff.pdf"},{"key":"irv210001r74","unstructured":"Centers for Medicare & Medicaid Services. Medicare provider utilization and payment data: part D prescriber. Centers for Medicare & Medicaid Services. Updated August 31, 2021. Accessed May 8, 2021. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Part-D-Prescriber"},{"key":"irv210001r75","unstructured":"Mallinckrodt Pharmaceuticals. Acthar\u00ae Gel (repository corticotropin injection). clinical benefit to appropriate patients. March 27, 2019. Accessed June 2, 2021. https:\/\/www.mallinckrodt.com\/globalassets\/images\/acthar\/h.p.-acthar-gel-clinical-value-presentation-03-27-19.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2787088\/jamainternal_tran_2021_rv_210001_1643648274.28546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T16:17:19Z","timestamp":1644250639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2787088"}},"subtitle":["A Scoping Review"],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.7171","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}